Merck reported solid Q2 results with growth in key areas like KEYTRUDA and ZEPATIER, and raised its non-GAAP EPS guidance, reflecting confidence in its strategic initiatives. Management's positive tone and successful product launches are likely to bolster investor sentiment in the short term.

[1]